Cancer Letters 591 (2024) 216894

Contents lists available at ScienceDirect

Cancer Letters

journal homepage: www.elsevier.com/locate/canlet

Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies

Mohamed El-Tanani [a,*], Syed Arman Rabbani [a], Rasha Babiker [b], Imran Rangraze [c], Sumedha Kapre [d], Sushesh Srivastsa Palakurthi [d], Abdullah M. Alnuqaydan [e], Alaa A. Aljabali [f], Manfredi Rizzo [g], Yahia El-Tanani [h], Murtaza M. Tambuwala [a,i,**]

[a] College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates
[b] Physiology Department, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras-al-Khaimah, United Arab Emirates
[c] Internal Medicine Department, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras-al-Khaimah, United Arab Emirates
[d] Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, Kingsville, TX, 78363, USA
[e] Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia
[f] Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid, 21163, Jordan
[g] Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Palermo, Italy
[h] Medical School, St George's University of London, Cranmer Terrace, Tooting, London, SW17 0RE, UK
[i] Lincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln, LN6 7TS, UK

A B S T R A C T

This comprehensive review delves into the pivotal role of the tumor microenvironment (TME) in cancer metastasis and therapeutic response, offering fresh insights into the intricate interplay between cancer cells and their surrounding milieu. The TME, a dynamic ecosystem comprising diverse cellular and acellular elements, not only fosters tumor progression but also profoundly affects the efficacy of conventional and emerging cancer therapies. Through nuanced exploration, this review illuminates the multifaceted nature of the TME, elucidating its capacity to engender drug resistance via mechanisms such as hypoxia, immune evasion, and the establishment of physical barriers to drug delivery. Moreover, it investigates innovative therapeutic approaches aimed at targeting the TME, including stromal reprogramming, immune microenvironment modulation, extracellular matrix (ECM)-targeting agents, and personalized medicine strategies, highlighting their potential to augment treatment outcomes.

Furthermore, this review critically evaluates the challenges posed by the complexity and heterogeneity of the TME, which contribute to variable therapeutic responses and potentially unintended consequences. This underscores the need to identify robust biomarkers and advance predictive models to anticipate treatment outcomes, as well as advocate for combination therapies that address multiple facets of the TME. Finally, the review emphasizes the necessity of an interdisciplinary approach and the integration of cutting-edge technologies to unravel the intricacies of the TME, thereby facilitating the development of more effective, adaptable, and personalized cancer treatments. By providing critical insights into the current state of TME research and its implications for the future of oncology, this review highlights the dynamic and evolving landscape of this field.

1. Introduction

Metastasis is a critical stage in the advancement of cancer, signifying a shift from a confined, potentially treatable illness to a widespread, frequently incurable state [1]. The process of cancer metastasis, in which malignant cells detach from their original location, migrate across the body via the bloodstream or lymphatic system, and establish new, more aggressive tumors in distant organs, is the principal factor contributing to global cancer-related death [2]. The capacity of cancer cells to undergo metastasis not only adds complexity to treatment approaches, but also greatly exacerbates patient prognoses, emphasizing the pressing necessity for a more profound understanding of the fundamental processes propelling this phenomenon [3].

The TME is a dynamic and complex environment that surrounds and interacts with tumor cells and plays a crucial role in cancer spread [4]. The TME consists of a diverse range of cellular and noncellular elements, including cancer cells, stromal cells (such as fibroblasts and mesenchymal stem cells), immune cells (such as T cells, B cells, macrophages,

* Corresponding author.
** Corresponding author.
E-mail addresses: eltanani@rakmhsu.ac.ae (M. El-Tanani), ami.alnuqaydan@qu.edu.sa (A.M. Alnuqaydan), m1906891@sgul.ac.uk (Y. El-Tanani), mtambuwala@lincoln.ac.uk (M.M. Tambuwala).

https://doi.org/10.1016/j.canlet.2024.216894
Received 13 February 2024; Received in revised form 29 March 2024; Accepted 11 April 2024
Available online 16 April 2024

and dendritic cells), the ECM, and numerous signaling molecules [5]. These components are not independent but instead interact in a continuous and complex manner that greatly affects tumor behavior, such as its development, survival, and ability to spread to other parts of the body [4].

ECM, which consists of a complex network of fibrous proteins and polysaccharides, offers both structural and biochemical assistance to cells located inside the TME [6]. It plays a pivotal role in controlling cell behavior and affecting processes such as cell adhesion, migration, and differentiation [7]. Changes in the content and rigidity of the ECM, which are frequently observed in tumors, might facilitate the development of cancerous growth and the spread of cancer cells to other parts of the body by influencing cellular signaling pathways and mechanical forces acting on cancer cells [8].

The stromal cells present in the TME facilitate tumor development and metastasis by releasing growth factors, cytokines, and chemokines, thereby creating a favorable environment for the tumor [9]. These chemicals contribute to the advancement of tumors by stimulating angiogenesis (creation of new blood vessels), regulating immunological responses, and increasing the survival and invasiveness of cancer cells [10].

Immune cells in the TME have dual functions. Tumors can manipulate the immune system to avoid detection and use certain immune cells to promote the growth and spread of cancer [11]. For instance, tumor-associated macrophages and myeloid-derived suppressor cells can inhibit anti-tumor immune responses and facilitate tumor angiogenesis and invasion [12].

A comprehensive understanding of the complex relationship between TME and the spread of cancer to other parts of the body (metastasis) is crucial for the advancement of novel treatment approaches [13]. By deciphering the mechanisms by which tumor cells engage with and control their immediate surroundings to promote the spread of cancer, scientists can identify novel areas for therapeutic intervention [14]. By focusing on the constituents of the TME or their interactions with tumor cells, it is possible to disrupt the supporting network on which tumors depend for their development and dissemination [15]. Possible techniques may involve suppressing the signaling pathways that facilitate communication between tumor and stromal cells, manipulating the immune response to strengthen the body's ability to fight tumors, or modifying the extracellular matrix to hinder the spread and invasion of tumors [16].

Ultimately, the tumor microenvironment is pivotal in governing the process of cancer metastasis, serving as a crucial intermediary in tumor advancement, and a viable candidate for therapeutic intervention [17]. A thorough understanding of the interactions between tumor cells and TME is crucial for the advancement of efficacious therapies targeted at suppressing metastasis and enhancing patient outcomes [18]. As research progresses in this area, it has the potential to reveal new therapeutic targets and tactics that might revolutionize cancer treatment and provide hope for people confronting this tremendous obstacle.

2. Components of the tumor microenvironment

TME is a complex and dynamic entity that plays a crucial role in cancer progression and metastasis. It comprises various components, including cancer cells, stromal cells, immune cells, and the ECM, each contributing uniquely to the tumor's behavior and interaction with the host organism [5,6]. Understanding these components and their interplay is critical for the development of more effective cancer therapies (Fig. 1). This review delves into the components of the TME by examining the latest research findings, conflicting results, and gaps in our current understanding.

2.1. Cancer cells

Cancer cells are characterized by genetic and epigenetic alterations



Fig. 1. Main components of tumor microenvironment (TME). The component consists of cancer cells, immune cells, stromal cells, and extracellular matrix (ECM). Cancer cells secrete factors that influence stromal and immune cells, induce pro-tumorigenic environment to target extracellular matrix ECM remodeling facilitating epithelial-to-mesenchymal transition (EMT) and tumor metastasis.

that not only drive tumorigenesis but also enable these cells to manipulate their surrounding environment [19]. Genetic changes, such as mutations in oncogenes and tumor suppressor genes, are well-documented drivers of cancer [20]. These alterations can confer a proliferative advantage, resistance to cell death, and the ability to induce angiogenesis [21]. Epigenetic modifications, including DNA methylation and histone modification, contribute to the oncogenic phenotype by regulating gene expression without altering the DNA sequence [22].

Recent studies have highlighted the ways in which cancer cells can modify the TME to their advantage. For instance, cancer cells can secrete factors that influence stromal and immune cells, thereby promoting a tumorigenic environment [23]. However, heterogeneity exists in the genetic and epigenetic profiles of cancer cells within a tumor, leading to variable interactions with the TME [24]. This heterogeneity often complicates treatment strategies and contributes to drug resistance [25].

Critical analysis of current research points to the need for a deeper understanding of the specific genetic and epigenetic changes that most significantly impact the TME. Although numerous studies have identified key alterations, the functional outcomes of many of these changes remain poorly understood. Additionally, most research has been conducted in vitro or in animal models, which may not fully replicate the complexity of human tumors [26,27].

2.2. Stromal cells

Stromal cells, including fibroblasts, endothelial cells, and mesenchymal stem cells, create a supportive environment for tumor growth and metastasis [10]. For example, cancer-associated fibroblasts (CAFs) are activated by cancer cells and contribute to tumor progression by secreting growth factors, modifying the ECM, and promoting angiogenesis. Endothelial cells are critical for tumor vascularization, providing the necessary nutrients and oxygen for tumor growth and offering a pathway for metastatic dissemination [28].

The role of stromal cells in the TME is complex, as they can both support [29] and restrain tumor growth [30], depending on the context. This duality presents a challenge in therapeutic targeting. Recent advancements have shed light on the signaling pathways mediating the interaction between stromal and cancer cells; however, the precise mechanisms remain elusive.

A critical analysis revealed that while the contributions of stromal

cells to tumor progression are well recognized, the regulatory networks governing their behavior in the TME are not fully understood. Studies often rely on simplified models that do not capture the full complexity of stromal cell interactions *in vivo* [31,32]. There is also a need to better understand the plasticity of stromal cells and their potential to revert to a nontumorigenic state.

2.3. Immune cells

Immune cells in the TME, such as T cells, B cells, macrophages, and dendritic cells, play dual roles. They can attack and destroy cancer cells, but can also be co-opted by the tumor to promote growth and metastasis [33]. For example, tumor-associated macrophages (TAMs) can be polarized by TME to a phenotype that supports tumor growth by suppressing immune responses and promoting angiogenesis and tissue remodeling [34].

The complexity of the immune landscape in the TME is a significant area of research, with studies showing both the tumor-suppressing and tumor-promoting roles of various immune cells [35]. The concept of immune checkpoint blockade has emerged from this research, offering promising therapeutic avenues [36]. However, the effectiveness of such therapies is variable, and, in some cases, immune cells can contribute to therapy resistance.

Critical insights from current research highlight the need for a more nuanced understanding of immune cell function within the TME. The interplay between different types of immune cells and their interactions with other TME components is not yet fully understood. Moreover, there is significant variability in the immune landscapes of different tumor types, and even within tumors of the same type, complicating the development of universal therapeutic strategies [32].

2.4. Extracellular matrix (ECM)

The ECM is a key component of the TME, providing structural support and regulating cell behavior through biochemical and mechanical cues. Cancer cells can remodel the ECM to promote tumor progression and enhance their migration and invasion capabilities [37]. Changes in ECM composition and stiffness have been shown to influence cancer cell phenotypes, including induction of EMT, a process critical for metastasis [38]. Recent studies have illuminated the complex role of ECM in cancer, showing how ECM remodeling can create pathways for cancer cell migration and protect tumor cells [37,38].

3. Mechanisms of tumor metastasis

The metastatic cascade is a multi-step process that enables cancer cells to spread from the primary tumor site to distant organs, is a key factor in the progression of cancer, and is a major cause of cancer-related mortality [1]. This complex process involves the local invasion and migration of cancer cells, intravasation into the bloodstream or lymphatic system, survival during circulation, extravasation into new tissues, and colonization and growth at secondary sites [39]. Each step is influenced by the TME and involves intricate mechanisms that cancer cells exploit to metastasize [40]. Fig. 2 provides an overview of the different steps of tumor metastasis. This review critically examines the mechanisms of tumor metastasis, highlights the role of the TME, and discusses emerging models and technologies that enhance our understanding of these processes.

3.1. Invasion and migration

The initial steps in the metastatic cascade involve local invasion and migration of cancer cells away from the primary tumor [41]. A key feature of this process is ECM degradation, which is facilitated by enzymes secreted by cancer cells, such as matrix metalloproteinases (MMPs). The breakdown of the ECM not only allows cancer cells to invade surrounding tissues but also releases bioactive molecules that can promote tumor progression [38].



Fig. 2. Overview of the steps of tumor metastasis: steps including (A) intravasation and margination; of tumor cells preceded by breakdown of the ECM, e.g. metalloproteinases (MMPs). (B) Intravasation and circulation; of tumor cells and tumor progression molecules, this process controlled by transcription factors (SNAIL, SLUG, TWIST, and ZEB1/2) altering E-cadherin and vimentin gene expression. (C) Extravasation and colonization; of the tumor create a niche with favorable microenvironment and growth factors for colonization.

Another critical aspect of invasion and migration is EMT, a process by which epithelial cancer cells acquire mesenchymal properties, enhancing their motility and invasiveness [42]. EMT is regulated by various factors within the TME including cytokines, growth factors, and ECM components. While the role of EMT in metastasis is supported by substantial evidence, recent studies have also highlighted the plasticity of cancer cells, which are capable of undergoing a reversible EMT process, adding complexity to targeting this mechanism therapeutically [43].

Invasion and migration are pivotal steps in the metastatic cascade of cancer cells [44]. These steps are orchestrated by a complex network of signaling pathways that regulate the breakdown of the ECM and the acquisition of a motile and invasive phenotype through EMT [42].

Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, play a crucial role in degrading various components of the ECM, facilitating cancer cell invasion into adjacent tissues. The activation of MMPs is regulated by signaling pathways, such as the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (MAPK/ERK) pathway, which can be stimulated by growth factors such as Epidermal Growth Factor (EGF) and Transforming Growth Factor beta (TGF-β) present in the TME [45].

The EMT process is governed by a set of core transcription factors, including zinc-finger transcription factor (SNAIL), Snail Family Transcriptional Repressor 2 (SLUG), basic helix-loop-helix (TWIST), and Zinc Finger E-Box Binding Homeobox 1 (ZEB1/2), which repress epithelial markers (e.g., E-cadherin) and induces the expression of mesenchymal markers (e.g., N-cadherin and vimentin) [46]. Activation of these transcription factors can be triggered by various signaling pathways, notably the TGF-β, Wnt/β-catenin, and Notch pathways. For instance, TGF-β binds to its receptor on cancer cells, activating SMAD signaling, which then upregulates SNAIL and SLUG, promoting EMT [47].

Additionally, the interaction between cancer cells and ECM components can activate integrin signaling, further enhancing cell motility and invasion. Integrins, through focal adhesion kinase (FAK) and Src, activate downstream pathways, such as PI3K/Akt and Rho GTPases, leading to cytoskeletal reorganization essential for cell migration [48].

The dynamic nature of these processes is underscored by the plasticity of cancer cells, which can reversibly transition between the

epithelial and mesenchymal states, complicating therapeutic targeting. Advanced technologies such as organ-on-a-chip systems and *in vivo* imaging have shed light on these intricate processes by mimicking the TME and providing real-time insights into cancer cell behavior during invasion and migration. These insights are crucial for developing targeted therapies that can effectively disrupt metastatic spread of cancer cells.

3.2. Intravasation and circulation

For cancer cells to metastasize, they must enter the bloodstream or lymphatic system in a process known as intravasation. This requires cancer cells to breach the vascular or lymphatic endothelium, facilitated by interactions with endothelial cells and alterations in vascular permeability, which are often induced by tumor-secreted factors [49].

Once in circulation, cancer cells face a hostile environment, including shear stress and immune surveillance, in which most cannot survive. The few that do are believed to adopt various strategies to evade detection, such as co-opting platelets to form protective cloaks around them [50]. The role of the TME in preparing cancer cells for this journey, through processes such as EMT and induction of a stem-like state, is a critical area of ongoing research.

Recent studies have used circulating tumor cell (CTC) assays and *in vivo* imaging to study cancer cells in the bloodstream, providing valuable insights into their survival strategies and interactions with blood components [51]. However, the exact mechanisms by which cancer cells survive and thrive in the circulatory system remain an active area of research.

3.3. Extravasation and colonization

The final steps in the metastatic cascade involve the exit of cancer cells from the bloodstream (extravasation) and establishment of new tumors in distant organs (colonization). Extravasation is mediated by interactions between cancer cells and the endothelium of distant tissues, involving adhesion molecules and secretion of factors that increase vascular permeability [52].

Colonization is arguably the most challenging step for metastasizing cancer cells, as they must adapt to a new microenvironment, evade immune surveillance, and acquire the resources necessary for growth [53]. The pre-metastatic niche concept, wherein primary tumor-derived factors precondition distant sites for metastasis, highlights the proactive role of TME in this process [54].

Critical evaluation of the current evidence reveals that, while the fundamental steps of the metastatic process are well characterized, many details, particularly regarding the molecular and cellular interactions involved, remain unclear. The contribution of the TME to each step of metastasis is a focus of intense research, with studies employing advanced models, such as patient-derived xenografts, organ-on-a-chip, and sophisticated imaging techniques, to unravel these complex interactions [55,56].

In conclusion, the metastatic cascade is a highly coordinated, multi-step process that involves intricate interactions between cancer cells and TME. Although significant advances have been made in understanding these mechanisms, many aspects remain to be elucidated. Emerging models and technologies promise to shed further light on this critical aspect of cancer biology, offering hope for the development of more effective therapies that target metastasis.

4. Influence of the TME on therapeutic response

TME plays a pivotal role not only in cancer progression and metastasis but also significantly influences the response to various therapeutic interventions [14]. The complexity and heterogeneity of the TME can impact the effectiveness of treatments, such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy, often leading to therapeutic resistance [57,58]. This review critically examines how TME influences therapeutic outcomes, explores the mechanisms of TME-mediated resistance, and assesses current strategies to overcome these challenges.

4.1. Influence of the TME on cancer therapies

4.1.1. Chemotherapy

The efficacy of chemotherapeutic agents can be significantly reduced by TME through various mechanisms. For instance, abnormal tumor vasculature often results in poor drug perfusion, which limits the delivery of chemotherapeutic agents to cancer cells. Additionally, acidic and hypoxic conditions within the TME can alter drug metabolism, leading to reduced drug efficacy and increased drug resistance [59].

Chemotherapy remains a cornerstone in the treatment of various cancers, offering the potential to rapidly divide cancer cells and reduce the tumor burden. However, the efficacy of chemotherapeutic agents is frequently compromised by the complex interplay with the TME, which can significantly influence drug delivery, metabolism, and the development of resistance [60].

One of the critical factors limiting the effectiveness of chemotherapy is the abnormal tumor vasculature. Tumors often stimulate the formation of new blood vessels in a process called angiogenesis. However, these newly formed vessels are typically disorganized, tortuous, and leaky. This aberrant vasculature leads to heterogeneous blood flow within the tumor, creating areas with poor perfusion. As a result, the delivery of chemotherapeutic agents to certain regions of the tumor is significantly reduced, diminishing the overall therapeutic effect and allowing pockets of cancer cells to survive, potentially giving rise to drug-resistant clones [61].

Moreover, the TME is characterized by regions of low pH and hypoxia, which arise due to the rapid proliferation of cancer cells, outstripping the supply of oxygen and nutrients. These acidic and oxygen-deprived conditions can further complicate chemotherapy by altering the drug metabolism and efficacy [62]. For instance, hypoxia can induce the expression of drug resistance genes and activate survival pathways in cancer cells, making them less susceptible to the cytotoxic effects of chemotherapy [63]. Similarly, an acidic TME can affect the ionization state of chemotherapeutic agents, influencing their absorption, distribution, and excretion and ultimately reducing their effectiveness [64].

Understanding TME-mediated mechanisms of resistance is crucial for improving the efficacy of chemotherapy. Efforts to normalize tumor vasculature, modulate the TME to reverse hypoxic conditions, or develop chemotherapeutic agents that retain their efficacy under such conditions are ongoing areas of research aimed at overcoming these challenges.

4.1.2. Radiotherapy

Radiotherapy relies on oxygen to generate reactive oxygen species (ROS), which damage the DNA in cancer cells. However, hypoxic regions within the TME can render cancer cells more resistant to radiation [65]. Moreover, radiotherapy can induce changes in the TME, such as increased fibrosis and changes in the immune cell population, which can further influence the therapeutic outcomes.

Radiotherapy is the cornerstone of the treatment of various cancers, exploiting the principle of using ionizing radiation to induce DNA damage in cancer cells, leading to cell death [66]. However, a critical factor in its efficacy is the presence of oxygen, which is required to generate reactive oxygen species (ROS) that can cause lethal DNA damage. TME, characterized by regions of hypoxia due to inadequate blood supply and rapid proliferation of tumor cells, can significantly impact the effectiveness of radiotherapy. Under hypoxic conditions, cancer cells become more resistant to the effects of radiation because the lack of oxygen reduces ROS formation, diminishes DNA damage, and allows cancer cells to survive and proliferate [67].

Furthermore, radiotherapy can induce profound changes in the TME,

which may influence therapeutic outcomes. For example, radiation can lead to increased fibrosis, characterized by the accumulation of fibrous connective tissue, which can create physical barriers for the delivery of therapeutic agents and immune cells. Additionally, radiotherapy can alter the composition and function of immune cells within the TME, potentially leading to both beneficial anti-tumorigenic and detrimental pro-tumorigenic effects, depending on the balance of elicited immune responses [68]. These changes in the TME highlight the complex interplay between radiotherapy and the tumor milieu, underscoring the need for strategies that consider and target the TME to enhance the efficacy of radiotherapy and improve cancer treatment outcomes.

4.1.3. Targeted therapy

Targeted cancer therapy is a form of personalized medicine that specifically targets cancer cells while minimizing the damage to healthy cells**.** Cancer cells exhibit specific molecular or genetic changes that distinguish them from healthy cells. Targeted therapies can selectively kill cancer cells or prevent their growth and spreading [69]. Unlike traditional chemotherapy, which can have widespread effects on the body and often cause side effects, targeted therapeutic drugs are designed to work more selectively and precisely, targeting specific molecules or pathways involved in cancer growth and progression [70] (Table 1).

In conclusion, although targeted therapies epitomize a more refined methodology for cancer treatment, their efficacy may be substantially undermined by TME [71]. The heterogeneity induced by the TME, along with its ability to activate alternative signaling pathways and modulate cancer cell responses through complex cell-cell and cell-matrix interactions, presents significant challenges to targeted therapy [57]. Understanding these interactions and formulating strategies to overcome TME-induced resistance are imperative to augment the effectiveness of targeted therapies in the treatment of cancer.

Table 1
Influence and mechanisms of the tumor microenvironment on the effectiveness of targeted therapies in cancer treatment.

Essential Components of Targeted Therapy Mechanism	TME Impact on Targeted Therapy: Pathways and Cellular Interactions	Impact of the TME on the efficacy of targeted therapies in cancer treatment	Targeted drugs and the genes they target
Interference with specific molecular targets in cancer progression	TME-induced heterogeneity leads to variations in the expression levels and activity of the target proteins across different tumor regions. Corresponding authors	TME-induced heterogeneity results in incomplete tumor regression and potential disease recurrence, as some cancer cells may be highly susceptible, while others with lower target expression are less affected.	**EGFR Inhibitors:** Erlotinib, Gefitinib, Afatinib - Target gene: EGFR
Inhibition of specific molecular targets in the growth, progression, and spread of cancer cells	Activation of alternative signaling pathways within the TME compensates for the inhibited pathway, providing escape routes for cancer cells from targeted inhibition.	Cancer cells exploit redundancy in cellular signaling networks under targeted therapy, developing resistance over time and limiting long-term efficacy.	Anti-claudin 18.2 antibody - **Target gene: Claudin**
Promise of high specificity and reduced side effects compared to traditional chemotherapy	Interactions between cancer cells and TME components (stromal cells, immune cells, extracellular matrix) modulate the response to targeted therapy.	TME interactions lead to the secretion of growth factors, cytokines, and signaling molecules, activating bypass pathways that provide escape routes for cancer cells from targeted therapy effects.	Hsp90 inhibitors - **Target gene: Hsp90**

4.1.4. Immunotherapy

The efficacy of immunotherapy, which utilizes the immune system to combat cancer, can be greatly impacted by the immunosuppressive characteristics of the TME. Immunosuppressive factors, including the presence of cells that suppress the immune system (such as regulatory T cells and myeloid-derived suppressor cells), the release of cytokines that inhibit the immune system, and the presence of chemicals that regulate immune responses, can weaken the immune response to cancer cells [72].

Immunotherapy has been developed as an innovative strategy for cancer treatment, using the body's immune system to recognize and eliminate cancer cells. Despite its considerable potential, immunotherapy is frequently impeded by the immunosuppressive attributes of the TME [73]. TME can establish a protective barrier around cancer cells, shielding them from immune-mediated eradication in many ways.

The immunosuppressive TME is characterized by the presence of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Tregs play a role in preserving immunological tolerance and have the ability to suppress the function of effector T cells, which are essential for targeting cancer cells [74]. However, MDSCs exert immunosuppressive effects by generating immunosuppressive substances and impeding the function of cytotoxic T cells and natural killer (NK) cells [75]. The aggregation of these cells in the tumor microenvironment (TME) might greatly impair the immune system's capacity to combat tumors [76].

TME is distinguished by the release of different immunosuppressive cytokines, including transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10). The presence of these cytokines can impede the growth and stimulation of immune cells, thereby diminishing the efficacy of immunotherapeutic approaches [77]. In addition, they can facilitate the transformation of inexperienced T-cells into Tregs, thereby enhancing the immunosuppressive milieu.

One significant obstacle to successful immunotherapy is the presence of immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) on tumor cells and programmed death 1 (PD-1) on T cells [78]. The interaction between programmed death PD-L1 and programmed cell PD-1 can result in T-cell fatigue, causing a loss of their ability to effectively target and eliminate cancer cells [79]. Immunotherapy concentrates on inhibiting these checkpoint molecules; however, the intricate interaction of signals in the TME may impede the efficacy of these therapies [80].

In summary, the immunosuppressive characteristics of TME present substantial obstacles to the effectiveness of immunotherapy. Immunosuppressive cells, inhibitory cytokines, and immunological checkpoint molecules work together to weaken immune response. This requires the development of new techniques to overcome these obstacles and to improve the effectiveness of immunotherapy in cancer treatment.

4.2. Mechanisms of TME-mediated resistance

Hypoxia-Induced Drug Resistance: Hypoxia, a common feature of TME, can induce the expression of genes associated with drug resistance, angiogenesis, and survival pathways, making cancer cells more resilient to therapy [81].

4.2.1. Immune evasion

TME can facilitate immune evasion through many methods, including the creation of an immunosuppressive environment, production of checkpoint molecules that hinder T-cell function, and modification of antigen presentation, resulting in decreased identification of

cancer cells by the immune system [82].

The TME is crucial in promoting immune evasion, a key element that allows cancer cells to flourish and multiply despite the body's immune surveillance capabilities. Immune evasion in the TME involves a complex strategy that weakens the capacity of the immune system to efficiently recognize and eliminate cancer cells [83].

TME utilizes the establishment of an immunosuppressive environment as a crucial strategy to facilitate immune evasion. This is accomplished by recruiting regulatory T cells (Tregs) and MDSCs, which inhibit the functional activities of cytotoxic T cells and NK cells [74,75]. In addition, the TME releases many immunosuppressive cytokines, including TGF-β and IL-10, which further inhibit the immune response and promote tumor advancement [77].

Immune checkpoint molecules, such as PD-L1 on tumor cells and PD-1 on T cells, are expressed in the TME to facilitate immune evasion [84]. The interplay between these chemicals induces the suppression of T-cell function, leading to T-cell fatigue and compromised immunological reactions against tumors.

Moreover, TME can modify the pathways of antigen presentation, thereby diminishing the detectability of cancer cells by the immune system. This process may entail the suppression of major histocompatibility complex (MHC) molecules in cancer cells, which hinders the display of tumor antigens and reduces detection by T cells [85].

Collectively, these pathways facilitate the TME to establish a defensive barrier around cancer cells, thereby enabling them to avoid immune recognition and elimination. Consequently, this presents considerable obstacles to cancer immunotherapy approaches that seek to revive the immune response against tumors.

4.2.2. Physical barriers

The ECM and cellular components of TME can act as physical barriers to drug delivery. A dense ECM can impede the penetration of therapeutic agents, whereas cellular components can absorb or metabolize drugs before they reach their intended targets [86].

The ECM and cellular constituents of the TME constitute significant physical barriers that can hinder the delivery and efficacy of chemotherapeutic agents [87]. The ECM, a complex network of fibrous proteins and polysaccharides, provides structural support to cells within the TME, but can also impede the diffusion of therapeutic molecules, especially those of larger sizes. This dense and often cross-linked matrix not only restricts drug penetration, but can also create a high interstitial fluid pressure that further limits drug distribution within the tumor [88].

Moreover, cellular components of the TME, including cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and other stromal cells, contribute to this barrier effect. These cells can absorb or metabolize chemotherapeutic drugs, effectively reducing the concentration of the agents that reach cancer cells. Additionally, these stromal cells can secrete various ECM components and modulate the ECM structure, complicating drug delivery [89]. Fig. 3 presents an overview of the different pathways that facilitate immune evasion and physical barriers to drug delivery in the TME.

The challenge posed by these physical barriers necessitates innovative approaches to enhance drug delivery, such as the development of nanoparticles and other drug carrier systems designed to penetrate the ECM or the use of agents that can modulate the ECM's structure to improve drug access. Overcoming these barriers is critical for improving the efficacy of chemotherapy and other therapeutic agents in treating solid tumors.

4.3. Overcoming TME-mediated resistance

Current strategies to counteract TME-mediated resistance include the development of combination therapies that target both cancer cells and components of the TME as well as the design of novel agents that specifically target the TME.

4.3.1. Combination therapies

Combining conventional therapies with agents that target the TME, such as angiogenesis inhibitors or ECM-modulating enzymes, can enhance drug delivery and reduce drug resistance. Additionally, combining immunotherapy with treatments that modulate the immunosuppressive TME can enhance the immune response against cancer cells [90].

Combination therapies that integrate conventional cancer treatments with agents targeting the TME represent a cutting-edge approach



Fig. 3. Overview of pathways facilitates Immune Evasion and drug delivery limitations in TME; the cellular components of the TME immunity suppressors, act as a barrier limit diffusion of therapeutic molecules. PD-L1: Programmed death-ligand 1; TGF β: Transforming growth factor; IL: Interleukin; MHC I; Major Histocompatibility Complex; MDSC: Myeloid-derived suppressor cell; NK: Natural killer; Regulatory T cell.

in oncology to overcome the inherent limitations of standalone therapies [91]. The strategic pairing of these treatments seeks to dismantle the protective barriers of the TME, enhance the efficacy of conventional therapies, and mitigate the resistance mechanisms [18].

Angiogenesis inhibitors aim to curtail the formation of new blood vessels within tumors, exemplifying this approach when combined with traditional chemotherapeutics or targeted therapies [92]. By inhibiting angiogenesis, these agents can normalize chaotic tumor vasculature and improve oxygenation and drug delivery to the tumor site. This normalization can alleviate hypoxia, a condition that not only promotes resistance to radiotherapy and certain chemotherapeutic agents but also fosters a more aggressive tumor phenotype [93].

In parallel, the deployment of ECM-modulating enzymes alongside standard treatments addresses the physical impediments to drug penetration posed by the dense and fibrous extracellular matrix (ECM) characteristic of many solid tumors. By breaking down key ECM components, these enzymes can enhance the permeability of the tumor mass, facilitating a deeper and more uniform distribution of therapeutic agents [94].

The realm of immunotherapy has seen promising advancements in combination strategies. By pairing immune checkpoint inhibitors with agents that diminish the immunosuppressive elements of the TME, such as T-regulatory cells and myeloid-derived suppressor cells, these therapies can effectively unleash the immune system against cancer cells [95]. Recent clinical trials have explored such combinations, revealing synergistic effects that amplify the antitumor immune response and offer new hope to patients with cancers previously deemed resistant to immunotherapy [96,97].

These combination therapies underscore the importance of a multifaceted attack in cancer treatment that targets both malignant cells and their supportive TME. These innovative strategies have the potential to significantly improve patient outcomes by disrupting the complex interplay between tumor cells and their environment, marking a pivotal shift in the paradigm of cancer therapy.

4.3.2. *Novel agents targeting the TME*

Researchers are developing novel therapeutic agents that specifically target components of the TME, such as drugs that normalize tumor vasculature, inhibitors of ECM remodeling enzymes, and agents that deplete immunosuppressive cells within the TME [98].

The development of novel therapeutic agents that specifically target the TME is a burgeoning area of cancer research. These innovative approaches are designed to disrupt the supportive network within the TME, thereby hindering tumor growth and metastasis and enhancing the efficacy of conventional cancer treatments [15].

One focus has been on agents that normalize tumor vasculature. Tumors often stimulate the formation of abnormal, leaky blood vessels, which can lead to poor oxygenation and nutrient delivery within the tumor as well as hinder drug delivery [61]. Agents that normalize these blood vessels can improve perfusion and oxygenation, reduce interstitial pressure, and facilitate the delivery of chemotherapeutic agents and immunotherapies to the tumor site [99].

Inhibitors of ECM remodeling enzymes are also being actively developed. The ECM in tumors is often denser and more cross-linked than that in normal tissues, creating a physical barrier to drug penetration and contributing to the development of resistance. By inhibiting enzymes involved in ECM remodeling, such as MMPs, these agents aim to reduce ECM density, thereby improving the therapeutic access to tumor cells [100].

Additionally, there is growing interest in agents that deplete immunosuppressive cells within the TME. The presence of Tregs and MDSCs significantly dampens the immune response against tumors. Therapeutic agents that can selectively deplete these immunosuppressive cell populations or inhibit their functions have the potential to reactivate the immune system's ability to fight cancer [101]. Fig. 4 shows the therapeutic agents that target different components of the TME.



Fig. 4. Therapeutic agents that target components of the TME, such as vessels, specific tumors enzymes, or inhibitors of immunosuppressive cells in the TME.

These novel agents targeting the TME are at various stages of development, and some are already in clinical trials. Their success could revolutionize cancer treatment by offering new ways to enhance the effectiveness of existing therapies, overcome drug resistance, and improve patient outcomes [102]. The ongoing challenge lies in understanding the complex dynamics of the TME to identify the most effective targets and to develop agents that can selectively modulate the TME without adversely affecting normal tissue function.

4.3.3. *Critical insights*

While these strategies are promising, they also present significant challenges. The complexity and heterogeneity of TME can lead to variable responses among patients, making it difficult to predict therapeutic outcomes. Furthermore, targeting the TME can have unintended consequences, such as the potential for increased metastasis due to alterations in tumor architecture or the induction of an inflammatory response that can promote tumor growth [14].

Moreover, there is a need for better biomarkers to predict the response to therapies targeting the TME and monitor the evolution of the TME in response to treatment. The development of more sophisticated models that accurately recapitulate the human TME is crucial for preclinical evaluation of these strategies.

While targeting the TME represents a promising frontier in cancer therapy, several critical insights have highlighted the challenges inherent in these strategies. TME is characterized by its remarkable complexity and heterogeneity, not only between different types of cancer but also within individual tumors. This diversity can lead to variable therapeutic responses among patients, complicating the prediction of outcomes and personalization of treatment strategies [103].

Furthermore, interventions aimed at modifying TME may have unintended consequences. For instance, disrupting the ECM or tumor vasculature to improve drug delivery could inadvertently enhance tumor cell dissemination, potentially increasing the risk of metastasis [87]. Similarly, strategies that modulate the immune components of the TME could trigger inflammatory responses that paradoxically might support tumor growth and progression by providing cancer cells with growth-stimulating signals [104].

Reliable biomarkers are needed to overcome these challenges. Biomarkers that can predict a patient's response to TME-targeted therapies are invaluable for selecting the most appropriate treatment regimen [105]. Additionally, monitoring the dynamic changes within the TME in response to therapy could offer insights into treatment efficacy and the development of resistance.

Advancing these therapeutic strategies hinges on the development of sophisticated models that accurately mimic the human TME [106]. Current preclinical models often fail to capture the full complexity of

TME, which can limit their predictive value for clinical outcomes. The creation of more representative models, possibly through advanced tissue engineering and organoid technology, could significantly enhance preclinical evaluation of novel TME-targeted therapies [107,108].

In summary, while targeting the TME offers a path to more effective cancer treatments, realizing this potential will require a deeper understanding of the complexity of the TME, development of predictive biomarkers, and creation of more accurate preclinical models. These challenges underscore the need for a multidisciplinary approach that integrates insights from oncology, immunology, and bioengineering to devise strategies that can safely and effectively manipulate the TME for therapeutic benefit.

5. Emerging therapeutic strategies targeting the TME

Emerging therapeutic strategies that target the TME represent a frontier in cancer treatment, offering new hope in the battle between tumor progression and metastasis [17]. These approaches aim to disrupt the supportive network that tumors exploit for growth, invasion, and resistance to conventional therapies. This review highlights novel therapeutic avenues, including stromal reprogramming, modulation of the immune microenvironment, ECM-targeting agents, and personalized medical approaches, providing a critical evaluation of their clinical potential, challenges, and future directions.

5.1. Stromal reprogramming

Stromal cells present in the TME, including cancer-associated fibroblasts (CAFs) and mesenchymal stem cells, play crucial roles in promoting tumor development and metastasis. Stromal reprogramming techniques seek to either suppress the cancer-promoting activities of these cells or transform them into cells that hinder tumor growth [109]. For example, medicines that specifically target the signaling pathways responsible for the interaction between cancer and stromal cells, such as TGF-β inhibitors, have demonstrated potential in preclinical models [110]. They can reverse the activated state of CAFs and decrease their capacity to promote tumor growth.

Stromal reprogramming is a new treatment strategy that focuses on modifying the supporting cells in the TME, namely cancer-associated fibroblasts (CAFs) and mesenchymal stem cells (MSCs), which play crucial roles in tumor growth and spread [111]. Stromal cells aid in the development of a tumor-promoting environment by releasing growth factors and cytokines and modifying the ECM, thereby promoting the advancement of cancer.

Current research has prioritized investigating methods to modify the behavior of these stromal cells, shifting them from a condition that promotes tumor growth to one that inhibits tumor growth. One effective strategy is to use inhibitors that target transforming growth factor-beta (TGF-β). TGF-β plays a crucial role as a cytokine in activating CAFs and inhibiting immunological responses in TME [112]. Preclinical studies have demonstrated that blocking TGF-β signaling can reverse the activated characteristics of cancer-associated fibroblasts (CAFs), reducing their capacity to promote tumor development and enhancing the vulnerability of tumors to alternative treatment approaches [110].

These techniques for altering stromal cells are now in the first phase of advancement and are mostly studied in preclinical environments. The difficulty arises in specifically targeting the tumor-promoting actions of stromal cells while preserving their essential physiological roles in healthy tissues. As this research advances, stromal reprogramming has the potential to greatly improve the efficacy of current cancer treatments by disrupting the supporting network on which tumors depend for their development and spread.

5.2. Modulation of the immune microenvironment

Modulation of the immune microenvironment is crucial for enhancing the efficacy of cancer therapy [113]. The immune microenvironment plays a crucial role in the TME, since it has the capacity to both inhibit and facilitate tumor development. Approaches to manipulate this setting include the use of checkpoint inhibitors to revive the body's natural defense mechanisms against tumors [114], the implementation of vaccines to activate the immune system against tumor-specific substances [115], and the adoption of adoptive cell therapies such as CAR-T cell therapy, which entails the introduction of genetically modified immune cells with augmented tumor-eradicating abilities [116]. Table 2 provides a structured overview of the microenvironmental manipulation methods.

However, immunosuppressive processes in the TME might hinder the efficacy of immune-modulating therapy [117]. The TME can protect tumors from being detected and attacked by the immune system using many tactics, such as attracting regulatory T cells and myeloid-derived suppressor cells, and releasing immunosuppressive cytokines. This requires the creation of combination medicines that not only stimulate the immune response, but also demolish the protective barriers of the TME against immune cells.

In summary, although efforts to regulate the immune microenvironment have demonstrated substantial potential in the treatment of cancer, the challenge of overcoming the immunosuppressive impact of the TME persists. Future research should prioritize the investigation of combination therapies and aim to obtain a more comprehensive knowledge of the complexity of the TME. This will play a vital role in improving the effectiveness of immune-based cancer treatment.

5.3. ECM targeting agents

ECM plays a crucial role in tumor progression and metastasis, providing structural support and biochemical cues that promote cancer cell migration and invasion [118]. Agents targeting the ECM aim to disrupt these processes, either by degrading ECM components to reduce tumor stiffness and improve drug penetration, or by inhibiting the enzymes responsible for ECM remodeling, such as MMP inhibitors [119]. While these approaches have shown potential in preclinical studies, clinical translation has been challenging owing to issues with specificity and side effects, underscoring the need for more targeted delivery methods.

Targeting the ECM has emerged as a strategic approach to impede tumor progression and metastasis [119]. The ECM not only provides structural integrity to tissues, but also plays an active role in cancer cell behavior, facilitating migration and invasion. Agents designed to target the ECM function through various mechanisms, including the degradation of ECM components to alleviate tumor stiffness, which can otherwise act as a physical barrier to drug delivery [120]. Additionally, inhibiting enzymes responsible for ECM remodeling, such as MMPs, is another strategy to prevent the ECM from facilitating tumor growth and spread [121].

Despite the promising potential of ECM targeting agents in preclinical models, their transition to clinical application faces significant hurdles. One of the primary challenges is achieving sufficient specificity to target tumor-associated ECM components without affecting the normal ECM, which is crucial for the integrity and function of healthy tissues [122]. The broad activity of MMP inhibitors, for example, has led to side effects that limit their therapeutic window. Moreover, the complexity of ECM interactions within the tumor microenvironment necessitates a more nuanced understanding to effectively leverage these agents in cancer therapy. Consequently, there is an ongoing effort to develop more targeted delivery systems and to identify ECM components that are uniquely altered in tumors, which could serve as more specific targets for therapy.

5.4. Personalized medicine approaches

The heterogeneity of the TME across different tumors and patients

Table 2
Novel strategies in cancer immunotherapy: Mechanisms and targets for modulating the tumor microenvironment.

Microenvironment Manipulation Methods	Examples of Drugs	Mechanism of Action	Target Cancer Cells
Immune checkpoint blockade	• Pembrolizumab • Nivolumab, • Ipilimumab	Target the PD-1/PD-L1 and CTLA-4 pathways, stimulating the immune system to counteract the suppression of immune responses against tumors.	Various cancers, particularly those with a substantial number of mutations, such as melanoma and non-small cell lung cancer.
Cytokine therapy	• Interleukin-2 (IL-2) • Interferon-alpha (IFN-alpha)	• Stimulates T-cell proliferation and activation • Enhances immune cell function and anti-tumor activity	• Melanoma, renal cell carcinoma • Melanoma, leukemia, Kaposi sarcoma
Tumor-associated macrophage (TAM) modulation	CSF-1R inhibitors • Emactuzumab • Pexidartinib	Inhibits CSF-1R, reducing recruitment and polarization of TAMs	Explored in clinical trials for various solid tumors including • Breast cancer • Ovarian cancer • Pancreatic cancer • Lung cancer • Melanoma
	Colony-stimulating factor 1 (CSF-1) inhibitors • PLX3397 (pexidartinib) • AMG820	Inhibits CSF-1, reducing TAM activity and promoting anti-tumor immunity	Explored in preclinical and clinical studies for a range of cancers • Breast cancer • Ovarian cancer • Pancreatic cancer • Colorectal cancer • Prostate cancer • Glioblastoma • Lung cancer • Melanoma
Angiogenesis inhibition	• Bevacizumab	Blocks VEGF, inhibiting angiogenesis and tumor growth	Various, including colorectal, lung, breast cancer
	• Sunitinib	Inhibits multiple receptor tyrosine kinases involved in angiogenesis	Renal cell carcinoma, gastrointestinal stromal tumors
	• Sorafenib	Inhibits RAF/MEK/ERK pathway and receptor tyrosine kinases	Renal cell carcinoma, hepatocellular carcinoma
	• Ramucirumab	Blocks VEGFR-2, inhibiting angiogenesis	Gastric cancer, non-small cell lung cancer
Stromal targeting	Hedgehog pathway inhibitors: • Vismodegib • Sonidegib	Inhibits the hedgehog signaling pathway, disrupting stromal support	Basal cell carcinoma, medulloblastoma
	Fibroblast activation protein (FAP) inhibitors	Inhibits FAP, disrupting stromal support	Pancreatic cancer, colorectal cancer
	• Talabostat (PT-100) • PT-630		
Hypoxia targeting	HIF inhibitors • Roxadustat • Belzutifan	Inhibits hypoxia-inducible factor (HIF), reducing hypoxia-driven tumor progression	Various cancer types
	Hypoxia-activated prodrugs • Tirapazamine • Evofosfamide	Become cytotoxic in hypoxic conditions, targeting hypoxic regions within tumors	Various cancer types
ECM (Extracellular Matrix) targeting	Matrix Metalloproteinase (MMP) Inhibitors • Marimastat • Batimastat	Block the activity of MMPs, thereby preventing ECM degradation and inhibiting tumor cell migration and invasion.	Breast cancer, prostate cancer, colorectal cancer and melanoma.
	Integrin Inhibitors Cilengitide Volociximab	• Targets αvβ3 and αvβ5 integrins, inhibiting tumor angiogenesis and metastasis • Inhibits α5β1 integrin, disrupting tumor cell adhesion and migration.	• Glioblastoma, melanoma, and other solid tumors • Renal cell carcinoma, colorectal cancer, and melanoma.
Therapeutic Vaccinations	Sipuleucel-T	An autologous cellular immunotherapy designed to stimulate the patient's immune system to target prostate cancer cells	Prostate cancer
	GVAX	A whole-cell cancer vaccine composed of irradiated tumor cells genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF).	Various cancers, including pancreatic cancer, prostate cancer, and lung cancer.
	Tumor-associated antigen (TAA) vaccines	TAA vaccines target specific tumor-associated antigens expressed by cancer cells.	HER2/neu (HER2-positive breast cancer), NY-ESO-1 (various cancers), and MUC1 (pancreatic cancer, breast cancer, and others

has prompted interest in personalized medicine approaches, which tailor therapies based on the specific characteristics of an individual's tumor [123]. This includes biomarker-driven therapies that target specific molecular alterations within the TME and the use of patient-derived tumor models, such as organoids and patient-derived xenografts, to test and optimize therapeutic regimens [124,125]. These approaches hold great promise for improving treatment efficacy and reducing toxicity by ensuring that patients receive therapies most likely to benefit them based on the unique composition of their TME.

Personalized medicine approaches are gaining traction in oncology due to the recognition of the significant heterogeneity present within the TME of different patients [126]. These strategies aim to customize cancer treatment based on the unique molecular and cellular characteristics of an individual's tumor, thereby enhancing therapeutic efficacy, and minimizing adverse effects.

Biomarker-driven therapies represent a cornerstone of personalized medicine, where specific molecular markers within the TME are identified and targeted with tailored treatments [127]. For example, the presence of particular genetic mutations or overexpressed proteins can guide the selection of targeted therapies, ensuring that the treatment regimen is specifically effective against the tumor's unique profile [128].

Moreover, the use of patient-derived models, such as organoids and patient-derived xenografts (PDXs), is revolutionizing the preclinical evaluation of cancer therapies. These models closely mimic the patient's own tumor, including its TME, thereby providing a more accurate prediction of how the tumor might respond to various treatments [129]. By testing therapeutic regimens on these patient-specific models before actual clinical application, clinicians can identify the most promising treatment strategies, significantly increasing the likelihood of successful outcomes.

Personalized medicine approaches underscore the importance of understanding and targeting the TME's intricacies. By tailoring treatments to the individual characteristics of each patient's tumor, personalized medicine holds the potential to significantly improve the precision, effectiveness, and safety of cancer therapies [130].

5.5. Critical insights

While emerging therapeutic strategies targeting the TME offer considerable promise, several challenges remain. The complexity and heterogeneity of the TME can make it difficult to identify universal targets, and interventions that disrupt the TME may have unintended consequences on normal tissue homeostasis. Moreover, the dynamic nature of the TME and its ability to evolve in response to therapy can lead to resistance, necessitating adaptive treatment strategies that can anticipate and counteract these changes.

Recent clinical trials targeting the TME have yielded mixed results, with some strategies showing significant benefits in specific tumor types or subsets of patients, while others have failed to demonstrate efficacy [15]. These outcomes highlight the importance of patient selection, the need for reliable biomarkers to predict response, and the potential of combination therapies that target multiple components of the TME.

The future direction of research in this area will likely focus on further elucidating the complex interactions within the TME, identifying new therapeutic targets, and developing more sophisticated models for predicting treatment response. Additionally, the integration of emerging technologies, such as artificial intelligence and machine learning, with large-scale genomic and proteomic data, could offer new insights into the TME and facilitate the design of more effective and personalized therapeutic strategies [131].

In conclusion, targeting the TME represents a promising avenue for improving cancer treatment outcomes. However, the success of these strategies will depend on a deeper understanding of the TME's complexity, the development of more precise and adaptable therapeutic approaches, and the ability to personalize treatments based on the unique characteristics of each patient's tumor. As research in this field progresses, it holds the potential to transform the landscape of cancer therapy, moving towards more effective, less toxic, and highly personalized treatment regimens.

Emerging therapeutic strategies targeting the TME are at the forefront of oncology research, offering new pathways to combat cancer's adaptive and resilient nature. These strategies, however, confront the inherent complexity and heterogeneity of TME, posing significant challenges to their universal applicability and efficacy. The TME's intricate network of cellular and molecular interactions not only varies significantly among different tumor types and individual patients but also dynamically evolves in response to therapeutic interventions, often leading to the development of resistance mechanisms [132].

One of the critical hurdles in targeting TME is the potential for unintended consequences on normal tissue homeostasis. Since many components of the TME, such as stromal cells and extracellular matrix molecules, are also present in healthy tissues, there is a risk that targeting these components could disrupt normal physiological processes, leading to adverse effects. Furthermore, the dynamic nature of the TME, characterized by its ability to adapt and reprogram in response to therapeutic pressures, necessitates the development of adaptive and flexible treatment strategies that can foresee and mitigate the emergence of resistance [133].

Clinical trials targeting various aspects of the TME have shown mixed results, underscoring the importance of precise patient selection, the identification of reliable biomarkers to predict therapeutic response, and the potential benefits of combination therapies. These combination approaches, which target multiple facets of the TME, may offer synergistic effects that enhance treatment efficacy and overcome resistance mechanisms [15].

Future research is poised to delve deeper into the TME's complexities, aiming to uncover novel targets and develop more sophisticated predictive models. The integration of cutting-edge technologies, such as artificial intelligence and advanced genomic analysis, holds promise for unraveling the TME's complexities and tailoring more effective, personalized treatment regimens [134].

In summary, while the path to effectively targeting the TME is fraught with challenges, the potential rewards are significant. A deeper understanding of the TME, coupled with innovative therapeutic strategies and technologies, could revolutionize cancer treatment, leading to more effective, less toxic, and highly personalized approaches that significantly improve patient outcomes.

6. Conclusion and future directions

This review paper explores the complex connection between the TME and the spread of cancer to other parts of the body, which is a major factor in cancer-related deaths. The text emphasizes the diverse functions of the TME in promoting tumor development, aiding in the spread of cancer to other parts of the body, and impacting the effectiveness of cancer treatments. This article emphasizes the need of having a thorough understanding of the many components of the TME, such as cancer cells, stromal cells, immune cells, and the ECM. It highlights the significance of their dynamic interactions, which play a crucial role in the growth and advancement of cancer.

The TME's impact encompasses the efficacy of several treatment modalities, including chemotherapy, radiation, targeted therapy, and immunotherapy. The TME plays a crucial role in the development of resistance to therapy. This resistance can be caused by several mechanisms, such as drug resistance generated by low oxygen levels (hypoxia), evasion of the immune system, and physical obstacles that hinder the transport of drugs. These mechanisms have a substantial impact on the effectiveness of treatment. The review highlights the continuous endeavours to address these issues by utilizing combination therapy and innovative drugs that target the TME. Additionally, it acknowledges the possible unintended repercussions of interfering with the intricate

network of the TME.

The article discusses novel treatment techniques aimed at targeting the TME, including stromal reprogramming, immune microenvironment regulation, medicines that target the ECM, and personalized medicine tactics. These innovative approaches show potential in enhancing the effectiveness of treatments and improving the results for patients by specifically targeting the supporting network that tumors rely on for their development and spread. Nonetheless, an assessment is conducted to evaluate the therapeutic possibilities of these techniques, the difficulties encountered in their execution, and the findings derived from recent clinical trials. This evaluation aims to present an impartial perspective on the present status of medicines targeting the TME.

It emphasizes the necessity of a comprehensive comprehension of the TME to advance the development of more efficient cancer treatments. A comprehensive approach to cancer therapy is necessary due to the complicated interactions between the numerous cellular and non-cellular components of the TME, which is characterized by its complex and dynamic nature. This encompasses not only the specific targeting of the tumor cells, but also the manipulation of the adjacent microenvironment that facilitates the growth and spread of the tumor.

Additionally, it identifies future research objectives that emphasise the incorporation of multidisciplinary methodologies, integrating knowledge from cancer, immunology, cell biology, bioengineering, and computational biology. The collective endeavour is crucial for comprehending the intricacies of the TME and devising inventive treatment approaches that can precisely target the TME. Utilizing cutting-edge technology, including sophisticated imaging methods, single-cell sequencing, organ-on-a-chip models, and artificial intelligence, is highlighted as essential for obtaining profound understanding of the TME and discovering novel treatment targets.

Furthermore, the research highlights the promise of personalized medicine in customising medicines to the distinct attributes of an individual patient's TME. This strategy necessitates the identification of dependable biomarkers capable of forecasting therapy response, as well as the creation of patient-specific tumor models for the purpose of testing and refining treatment protocols. The objective is to transcend a universal approach to cancer therapy and progress towards tailored treatment strategies that take into account the specific intricacies of each patient's tumor and its milieu.

6.1. Navigating TME complexity in cancer

In critically analyzing the dynamic interplay between the TME and cancer metastasis, recent research findings have significantly advanced our understanding, shedding light on the intricate mechanisms that underpin cancer progression and response to therapy. This article has delved into the complexity of the TME, highlighting its components, the multifaceted processes of tumor metastasis, the influence of the TME on therapeutic outcomes, emerging therapeutic strategies targeting the TME, and the overarching implications for cancer biology and treatment. Throughout, we have critically evaluated the significance of these insights, acknowledging areas of ongoing debate and considering the translational potential of this body of research.

Recent studies underscore TME's critical role in facilitating cancer metastasis, revealing how cancer cells exploit the TME to evade immune surveillance, resist therapeutic agents, and colonize distant organs. The TME's components, including stromal cells, immune cells, the ECM, and various signaling molecules, create a supportive niche for tumor growth and dissemination. However, the heterogeneity and dynamism of the TME present substantial challenges, leading to controversies regarding the most effective targets for intervention and the best approaches to modulate the TME for therapeutic benefit.

The implications of these findings for cancer biology are profound, offering new perspectives on how cancers grow, spread, and respond to treatments. For instance, the concept of reprogramming the TME to render it hostile to cancer cells rather than supportive represents a paradigm shift in cancer therapy. Similarly, understanding the mechanisms of TME-mediated therapeutic resistance has opened avenues for developing strategies to overcome this resistance, such as combination therapies that target both tumor cells and the TME.

Areas of controversy within the field include the role of EMT in metastasis, with some studies suggesting it is a critical driver of metastatic dissemination, while others propose that cancer cells can metastasize without undergoing EMT. Additionally, the dual role of immune cells in promoting and inhibiting tumor growth underscores the complexity of targeting the immune microenvironment for cancer therapy. These debates highlight the necessity of a nuanced understanding of TME and its interactions with cancer cells, urging researchers to consider multiple perspectives and the diverse evidence supporting them.

The TME is characterized by remarkable heterogeneity and dynamism, which significantly influence the pathophysiology of different cancer types and their progression stages. This variability stems from the unique interactions between cancer cells, stromal cells, immune cells, extracellular matrix components, and various biochemical factors within the TME, all of which can vary widely across different tumor types and even within different regions of the same tumor. The heterogeneity of the TME can impact the generalizability of research findings, as therapeutic targets and strategies effective in one tumor context may not be applicable in another. This complexity underscores the challenge in developing universally effective cancer treatments and highlights the need for personalized therapeutic approaches that consider the specific characteristics of the TME in individual patients. Moreover, the dynamic nature of the TME, which evolves in response to both the progression of the disease and therapeutic interventions, further complicates the development of effective treatment strategies. Understanding the mechanisms driving TME heterogeneity and dynamics is crucial for the identification of reliable biomarkers and the development of adaptive treatment strategies that can anticipate and counteract changes within the TME. In summary, the heterogeneity and dynamic nature of the TME present significant challenges to cancer research and treatment, necessitating a more nuanced and personalized approach to therapy. For more detailed insights, exploring recent reviews and studies on the TME's role in cancer could provide a deeper understanding of these complexities.

Translating preclinical findings into successful clinical therapies presents significant challenges, particularly regarding the scalability of personalized medicine approaches. Key hurdles include the complexity of human biology not fully replicated in animal models or in vitro systems, leading to discrepancies between preclinical efficacy and clinical outcomes. Additionally, personalized medicine's reliance on detailed genetic, molecular, and environmental patient data raises issues of data management, privacy, and the need for advanced computational tools for analysis. The high cost and logistical demands of creating tailored therapies also pose significant barriers, making widespread implementation challenging. For a deeper exploration of these challenges, reviewing recent literature on the translation of cancer research from bench to bedside could provide valuable insights.

Manipulating the TME for therapeutic purposes raises significant ethical concerns and potential side effects. Ethical considerations revolve around the long-term impacts of altering the TME, potential off-target effects, and the equitable access to such personalized therapies. Side effects could range from unintended impacts on normal tissue homeostasis to the promotion of tumor resistance or aggressiveness due to the adaptive nature of cancer cells within the TME. These complexities underscore the need for careful evaluation and regulation of therapies targeting TME, ensuring they are both safe and accessible. For a comprehensive discussion, refer to recent bioethical literature on cancer therapy and TME manipulation.

CRediT authorship contribution statement

Mohamed El-Tanani: Writing – review & editing, Writing – original draft. **Syed Arman Rabbani:** Writing – review & editing, Writing – original draft. **Rasha Babiker:** Writing – original draft, Writing – review & editing. **Imran Rangraze:** Writing – original draft, Writing – review & editing. **Sumedha Kapre:** Writing – original draft, Writing – review & editing. **Sushesh Srivastsa Palakurthi:** Writing – original draft, Writing – review & editing. **Abdullah M. Alnuqaydan:** Writing – review & editing. **Alaa A. Aljabali:** Writing – original draft, Writing – review & editing. **Manfredi Rizzo:** Writing – original draft, Writing – review & editing. **Yahia El-Tanani:** Writing – original draft, Writing – review & editing. **Murtaza M. Tambuwala:** Writing – review & editing, Project administration, Writing – original draft.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] J. Fares, M.Y. Fares, H.H. Khachfe, H.A. Salhab, Y. Fares, Molecular principles of metastasis: a hallmark of cancer revisited, Signal Transduct. Targeted Ther. 5 (1) (2020 Mar 12) 1–17.

[2] P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nat. Med. 12 (8) (2006 Aug) 895–904.

[3] K. Ganesh, J. Massagué, Targeting metastatic cancer, Nat. Med. 27 (1) (2021 Jan) 34–44.

[4] K.E. de Visser, J.A. Joyce, The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth, Cancer Cell 41 (3) (2023 Mar 13) 374–403.

[5] N.M. Anderson, M.C. Simon, The tumor microenvironment, Curr. Biol. 30 (16) (2020 Aug 17) R921–R925.

[6] R. Wei, S. Liu, S. Zhang, L. Min, S. Zhu, Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers, Anal. Cell Pathol. 2020 (2020) 6283796.

[7] N.V. Popova, M. Jücker, The functional role of extracellular matrix proteins in cancer, Cancers 14 (1) (2022 Jan 4) 238.

[8] R.G. Rowe, S.J. Weiss, Navigating ECM barriers at the invasive front: the cancer cell-stroma interface, Annu. Rev. Cell Dev. Biol. 25 (2009) 567–595.

[9] B.S. Hill, A. Sarnella, G. D'Avino, A. Zannetti, Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer, Semin. Cancer Biol. 60 (2020 Feb) 202–213.

[10] Y. Zhao, M. Shen, L. Wu, H. Yang, Y. Yao, Q. Yang, et al., Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 14 (9) (2023 Sep 4) 1–24.

[11] V. Chew, H.C. Toh, J.P. Abastado, Immune microenvironment in tumor progression: characteristics and challenges for therapy, JAMA Oncol. 2012 (2012) 608406.

[12] S. Ostrand-Rosenberg, P. Sinha, Myeloid-derived suppressor cells: linking inflammation and cancer, J. Immunol. 182 (8) (2009 Apr 15) 4499–4506.

[13] Y. Xiao, D. Yu, Tumor microenvironment as a therapeutic target in cancer, Pharmacol. Ther. 221 (2021 May) 107753.

[14] R. Baghban, L. Roshangar, R. Jahanban-Esfahlan, K. Seidi, A. Ebrahimi-Kalan, M. Jaymand, et al., Tumor microenvironment complexity and therapeutic implications at a glance, Cell Commun. Signal. 18 (1) (2020 Apr 7) 59.

[15] C. Roma-Rodrigues, R. Mendes, P.V. Baptista, A.R. Fernandes, Targeting tumor microenvironment for cancer therapy, Int. J. Mol. Sci. 20 (4) (2019 Feb 15) 840.

[16] M. Binnewies, E.W. Roberts, K. Kersten, V. Chan, D.F. Fearon, M. Merad, et al., Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat. Med. 24 (5) (2018 May) 541–550.

[17] Q. Babar, A. Saeed, T.A. Tabish, M. Sarwar, N.D. Thorat, Targeting the tumor microenvironment: potential strategy for cancer therapeutics, Biochim. Biophys. Acta, Mol. Basis Dis. 1869 (6) (2023 Aug) 166746.

[18] M.Z. Jin, W.L. Jin, The updated landscape of tumor microenvironment and drug repurposing, Signal Transduct. Targeted Ther. 5 (1) (2020 Aug 25) 1–16.

[19] H. Takeshima, T. Ushijima, Accumulation of genetic and epigenetic alterations in normal cells and cancer risk, npj Precis Onc 3 (1) (2019 Mar 6) 1–8.

[20] A. Chatterjee, E.J. Rodger, M.R. Eccles, Epigenetic drivers of tumourigenesis and cancer metastasis, Semin. Cancer Biol. 51 (2018 Aug) 149–159.

[21] Y. Yao, W. Dai, Genomic instability and cancer, J. Carcinog. Mutagen. 5 (2014) 1000165.

[22] H. Shen, P.W. Laird, Interplay between the cancer genome and epigenome, Cell 153 (1) (2013 Mar 28) 38–55.

[23] C.M. Neophytou, M. Panagi, T. Stylianopoulos, P. Papageorgis, The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities, Cancers 13 (9) (2021 Apr 23) 2053.

[24] X. Hua, W. Zhao, A.C. Pesatori, D. Consonni, N.E. Caporaso, T. Zhang, et al., Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma, Nat. Commun. 11 (1) (2020 May 18) 2459.

[25] Fath M. Karami, A. Azargoonjahromi, A. Kiani, F. Jalalifar, P. Osati, Oryani M. Akbari, et al., The role of epigenetic modifications in drug resistance and treatment of breast cancer, Cell. Mol. Biol. Lett. 27 (1) (2022 Jun 28) 52.

[26] M.E. Katt, A.L. Placone, A.D. Wong, Z.S. Xu, P.C. Searson, In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform [Internet], Front. Bioeng. Biotechnol. 4 (2016). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751256/.

[27] T. Voskoglou-Nomikos, J.L. Pater, L. Seymour, Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models, Clin. Cancer Res. 9 (11) (2003 Sep 15) 4227–4239.

[28] M. Sarkar, T. Nguyen, E. Gundre, O. Ogunlusi, M. El-Sobky, B. Giri, et al., Cancer-associated fibroblasts: the chief architect in the tumor microenvironment, Front. Cell Dev. Biol. 11 (2023 Jan 30) 1089068.

[29] L. Monteran, Y. Zait, N. Erez, It's all about the base: stromal cells are central orchestrators of metastasis, 00235-2, Trends Cancer (23) (2023 Dec 9) S2405–S8033.

[30] A.D. Rhim, P.E. Oberstein, D.H. Thomas, E.T. Mirek, C.F. Palermo, S.A. Sastra, et al., Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma, Cancer Cell 25 (6) (2014 Jun 16) 735–747.

[31] W. Zhang, P. Huang, Cancer-stromal interactions, Cancer Biol. Ther. 11 (2) (2011 Jan 15) 150–156.

[32] Z.N. Zhou, P.J. Boimel, J.E. Segall, Tumor-stroma: in vivo assays and intravital imaging to study cell migration and metastasis, Drug Discov. Today Dis. Model. 8 (2–3) (2011) 95–112.

[33] T.F. Gajewski, H. Schreiber, Y.X. Fu, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol. 14 (10) (2013 Oct) 1014–1022.

[34] A. Mantovani, P. Allavena, F. Marchesi, C. Garlanda, Macrophages as tools and targets in cancer therapy, Nat. Rev. Drug Discov. 21 (11) (2022 Nov) 799–820.

[35] B.F. Zamarron, W. Chen, Dual roles of immune cells and their factors in cancer development and progression, Int. J. Biol. Sci. 7 (5) (2011) 651–658.

[36] C. Robert, A decade of immune-checkpoint inhibitors in cancer therapy, Nat. Commun. 11 (1) (2020 Jul 30) 3801.

[37] Z. Yuan, Y. Li, S. Zhang, X. Wang, H. Dou, X. Yu, et al., Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments, Mol. Cancer 22 (1) (2023 Mar 11) 48.

[38] J. Winkler, A. Abisoye-Ogunniyan, K.J. Metcalf, Z. Werb, Concepts of extracellular matrix remodelling in tumour progression and metastasis, Nat. Commun. 11 (1) (2020 Oct 9) 5120.

[39] L.A. Hapach, J.A. Mosier, W. Wang, C.A. Reinhart-King, Engineered models to parse apart the metastatic cascade, npj Precis Onc 3 (1) (2019 Aug 21) 1–8.

[40] S.E. Amos, Y.S. Choi, The cancer microenvironment: mechanical challenges of the metastatic cascade [Internet], Front. Bioeng. Biotechnol. 9 (2021). Available from: https://www.frontiersin.org/articles/10.3389/fbioe.2021.625859.

[41] P. Friedl, K. Wolf, Tumour-cell invasion and migration: diversity and escape mechanisms, Nat. Rev. Cancer 3 (5) (2003 May) 362–374.

[42] H. Son, A. Moon, Epithelial-mesenchymal transition and cell invasion, Toxicol. Res. 26 (4) (2010 Dec) 245–252.

[43] B. Bakir, A.M. Chiarella, J.R. Pitarresi, A.K. Rustgi, EMT, MET, plasticity and tumor metastasis, Trends Cell Biol. 30 (10) (2020 Oct) 764–776.

[44] J.J. Bravo-Cordero, L. Hodgson, J. Condeelis, Directed cell invasion and migration during metastasis, Curr. Opin. Cell Biol. 24 (2) (2012 Apr) 277–283.

[45] C. Gialeli, A.D. Theocharis, N.K. Karamanos, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J. 278 (1) (2011 Jan) 16–27.

[46] V. Ramesh, T. Brabletz, P. Ceppi, Targeting EMT in cancer with repurposed metabolic inhibitors, Trends Cancer 6 (11) (2020 Nov) 942–950.

[47] D. Ribatti, R. Tamma, T. Annese, Epithelial-mesenchymal transition in cancer: a historical overview, Transl Oncol 13 (6) (2020 Apr 22) 100773.

[48] J. Cooper, F.G. Giancotti, Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance, Cancer Cell 35 (3) (2019 Mar 18) 347–367.

[49] M.K. Sznurkowska, N. Aceto, The gate to metastasis: key players in cancer cell intravasation, FEBS J. 289 (15) (2022 Aug) 4336–4354.

[50] S.K. Kim, S.W. Cho, The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment, Front. Pharmacol. 13 (2022 May 24) 868695.

[51] R. Lawrence, M. Watters, C.R. Davies, K. Pantel, Y.J. Lu, Circulating tumour cells for early detection of clinically relevant cancer, Nat. Rev. Clin. Oncol. 20 (7) (2023 Jul) 487–500.

[52] X. Cheng, K. Cheng, Visualizing cancer extravasation: from mechanistic studies to drug development, Cancer Metastasis Rev. 40 (1) (2021 Mar) 71–88.

[53] J. Massagué, A.C. Obenauf, Metastatic colonization, Nature 529 (7586) (2016 Jan 21) 298–306.

[54] T.R. Cox, A. Gartland, J.T. Erler, The pre-metastatic niche: is metastasis random? BoneKEy Rep. 1 (2012 May 2) 80.

[55] X. Liu, Q. Su, X. Zhang, W. Yang, J. Ning, K. Jia, et al., Recent advances of organ-on-a-chip in cancer modeling research, Biosensors 12 (11) (2022 Nov 18) 1045.

[56] K. Seaman, Y. Sun, L. You, Recent advances in cancer-on-a-chip tissue models to dissect the tumour microenvironment, Med-X 1 (1) (2023 Oct 13) 11.

[57] E. Hirata, E. Sahai, Tumor microenvironment and differential responses to therapy, Cold Spring Harb Perspect Med. 7 (7) (2017 Jul 5) a026781.

[58] B. Son, S. Lee, H. Youn, E. Kim, W. Kim, B. Youn, The role of tumor microenvironment in therapeutic resistance, Oncotarget 8 (3) (2016 Dec 11) 3933–3945.

[59] E.C. Fiedler, M.T. Hemann, Aiding and abetting: how the tumor microenvironment protects cancer from chemotherapy, Annu. Rev. Cell Biol. 3 (1) (2019 Mar 4) 409–428.

[60] V. Salemme, G. Centonze, L. Avalle, D. Natalini, A. Piccolantonio, P. Arina, et al., The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity, Front. Oncol. 13 (2023 May 17) 1170264.

[61] R. Lugano, M. Ramachandran, A. Dimberg, Tumor angiogenesis: causes, consequences, challenges and opportunities, Cell. Mol. Life Sci. 77 (9) (2020 May) 1745–1770.

[62] D.A. Senthebane, A. Rowe, N.E. Thomford, H. Shipanga, D. Munro, M.A.M. Al Mazeedi, et al., The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer, Int. J. Mol. Sci. 18 (7) (2017 Jul 21) 1586.

[63] J.P. Cosse, C. Michiels, Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression, Anti Cancer Agents Med. Chem. 8 (7) (2008 Oct) 790–797.

[64] J.W. Wojtkowiak, D. Verduzco, K.J. Schramm, R.J. Gillies, Drug resistance and cellular adaptation to tumor acidic pH microenvironment, Mol. Pharm. 8 (6) (2011 Dec 5) 2032–2038.

[65] A. Menegakis, R. Klompmaker, C. Vennin, A. Arbusà, M. Damen, B. van den Broek, et al., Resistance of hypoxic cells to ionizing radiation is mediated in part via hypoxia-induced quiescence, Cells 10 (3) (2021 Mar 10) 610.

[66] R. Baskar, K.A. Lee, R. Yeo, K.W. Yeoh, Cancer and radiation therapy: current advances and future directions, Int. J. Med. Sci. 9 (3) (2012) 193.

[67] W. Boulefour, E. Rowinski, S. Louati, S. Sotton, A.S. Wozny, P. Moreno-Acosta, et al., A review of the role of hypoxia in radioresistance in cancer therapy, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 27 (2021 Nov 3).

[68] D. Zhao, Y. Mo, M.E. Neganova, Y. Aleksandrova, E. Tse, V.N. Chubarev, et al., Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers, Front. Cell Dev. Biol. 11 (2023 Oct 3) 1266537.

[69] T.A. Baudino, Targeted cancer therapy: the next generation of cancer treatment, Curr. Drug Discov. Technol. 12 (1) (2015) 3–20.

[70] Z. Zhou, M. Li, Targeted therapies for cancer, BMC Med. 20 (1) (2022 Mar 11) 90.

[71] P. Nallasamy, R.K. Nimmakayala, S. Parte, A.C. Are, S.K. Batra, M.P. Ponnusamy, Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis, Mol. Cancer 21 (1) (2022 Dec 22) 225.

[72] W. Zou, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat. Rev. Cancer 5 (4) (2005 Apr) 263–274.

[73] R. Barnestein, L. Galland, L. Kalfeist, F. Ghiringhelli, S. Ladoire, E. Limagne, Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness, OncoImmunology 11 (1) (2022) 2120676.

[74] J.H. Kim, B.S. Kim, S.K. Lee, Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy, Immune Netw 20 (1) (2020 Feb 11) e4.

[75] M. Dysthe, R. Parihar, Myeloid-derived suppressor cells in the tumor microenvironment, Adv. Exp. Med. Biol. 1224 (2020) 117–140.

[76] A. Labani-Motlagh, M. Ashja-Mahdavi, A. Loskog, The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses, Front. Immunol. 11 (2020) 940.

[77] L. Li, R. Yu, T. Cai, Z. Chen, M. Lan, T. Zou, et al., Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment, Int. Immunopharm. 88 (2020 Nov) 106939.

[78] Y. Han, D. Liu, L. Li, PD-1/PD-L1 pathway: current researches in cancer, Am. J. Cancer Res. 10 (3) (2020 Mar 1) 727–742.

[79] L. Chou, C.E. Callmann, D. Dominguez, B. Zhang, C.A. Mirkin, Disrupting the interplay between programmed cell death protein 1 and programmed death ligand 1 with spherical nucleic acids in treating cancer, ACS Cent. Sci. 8 (9) (2022 Sep 28) 1299–1305.

[80] J. Zhang, Z. Shi, X. Xu, Z. Yu, J. Mi, The influence of microenvironment on tumor immunotherapy, FEBS J. 286 (21) (2019 Nov) 4160–4175.

[81] B.A. Teicher, Hypoxia and drug resistance, Cancer Metastasis Rev. 13 (2) (1994 Jun) 139–168.

[82] A. Elmusrati, J. Wang, C.Y. Wang, Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma, Int. J. Oral Sci. 13 (1) (2021 Aug 2) 1–11.

[83] D.S. Vinay, E.P. Ryan, G. Pawelec, W.H. Talib, J. Stagg, E. Elkord, et al., Immune evasion in cancer: mechanistic basis and therapeutic strategies, Semin. Cancer Biol. 35 (Suppl) (2015 Dec) S185–S198.

[84] J. Eichberger, D. Schulz, K. Pscheidl, M. Fiedler, T.E. Reichert, R.J. Bauer, et al., PD-L1 influences cell spreading, migration and invasion in head and neck cancer cells, Int. J. Mol. Sci. 21 (21) (2020 Oct 29) 8089.

[85] K. Dhatchinamoorthy, J.D. Colbert, K.L. Rock, Cancer immune evasion through loss of MHC class I antigen presentation [cited 2024 Feb 8], Front. Immunol. 12 (2021), https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.636568.

[86] K. Khalaf, D. Hana, J.T.T. Chou, C. Singh, A. Mackiewicz, M. Kaczmarek, Aspects of the tumor microenvironment involved in immune resistance and drug resistance, Front. Immunol. 12 (2021) 656364.

[87] E. Henke, R. Nandigama, S. Ergün, Extracellular matrix in the tumor microenvironment and its impact on cancer therapy, Frontiers in Molecular Biosciences [Internet] (2020) [cited 2024 Feb 8];6. Available from: https://www.frontiersin.org/articles/10.3389/fmolb.2019.00160.

[88] S. Nizzero, A. Ziemys, M. Ferrari, Transport barriers and oncophysics in cancer treatment, Trends Cancer 4 (4) (2018 Apr) 277–280.

[89] Y. Arima, S. Matsueda, H. Saya, Significance of cancer-associated fibroblasts in the interactions of cancer cells with the tumor microenvironment of heterogeneous tumor tissue, Cancers 15 (9) (2023 Apr 28) 2536.

[90] Y.R. Murciano-Goroff, A.B. Warner, J.D. Wolchok, The future of cancer immunotherapy: microenvironment-targeting combinations, Cell Res. 30 (6) (2020 Jun) 507–519.

[91] K. Shee, W. Yang, J.W. Hinds, R.A. Hampsch, F.S. Varn, N.A. Traphagen, et al., Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer, J. Exp. Med. 215 (3) (2018 Mar 5) 895–910.

[92] J. Ma, D.J. Waxman, Combination of anti-angiogenesis with chemotherapy for more effective cancer treatment, Mol. Cancer Therapeut. 7 (12) (2008 Dec) 3670–3684.

[93] S. Ma, S. Pradeep, W. Hu, D. Zhang, R. Coleman, A. Sood, The role of tumor microenvironment in resistance to anti-angiogenic therapy, F1000Res 7 (2018 Mar 15) 326.

[94] J. Huang, L. Zhang, D. Wan, L. Zhou, S. Zheng, S. Lin, et al., Extracellular matrix and its therapeutic potential for cancer treatment, Signal Transduct. Targeted Ther. 6 (1) (2021 Apr 23) 153.

[95] K.M. Heinhuis, W. Ros, M. Kok, N. Steeghs, J.H. Beijnen, J.H.M. Schellens, Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors, Ann. Oncol. 30 (2) (2019 Feb 1) 219–235.

[96] H. Alemohammad, B. Najafzadeh, Z. Asadzadeh, A. Baghbanzadeh, F. Ghorbaninezhad, A. Najafzadeh, et al., The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer, Biomed. Pharmacother. 146 (2022 Feb 1) 112516.

[97] Y. Liang, L. Wang, P. Ma, D. Ju, M. Zhao, Y. Shi, Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors [cited 2024 Feb 10], Frontiers in Immunology [Internet] 14 (2023). Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1308264.

[98] H. Järveläinen, A. Sainio, M. Koulu, T.N. Wight, R. Penttinen, Extracellular matrix molecules: potential targets in pharmacotherapy, Pharmacol. Rev. 61 (2) (2009 Jun) 198–223.

[99] F.H. Al-Ostoot, S. Salah, H.A. Khamees, S.A. Khanum, Tumor angiogenesis: current challenges and therapeutic opportunities, Cancer Treatment and Research Communications 28 (2021 Jan 1) 100422.

[100] L.M. Coussens, B. Fingleton, L.M. Matrisian, Matrix metalloproteinase inhibitors and cancer: trials and tribulations, Science 295 (5564) (2002 Mar 29) 2387–2392.

[101] D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, G.J. Adema, The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells, Immunology 138 (2) (2013 Feb) 105–115.

[102] S. Zhong, J.H. Jeong, Z. Chen, Z. Chen, J.L. Luo, Targeting tumor microenvironment by small-molecule inhibitors, Translational Oncology 13 (1) (2020 Jan 1) 57–69.

[103] R. Ge, Z. Wang, L. Cheng, Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance, npj Precis. Oncol. 6 (1) (2022 May 4) 31.

[104] H. Patel, P. Nilendu, D. Jahagirdar, J.K. Pal, N.K. Sharma, Modulating secreted components of tumor microenvironment: a masterstroke in tumor therapeutics, Cancer Biol. Ther. 19 (1) (2017 Dec 8) 3–12.

[105] J. Su, L. Zhou, Z. Zhang, X. Xiao, Y. Qin, X. Zhou, et al., The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma, Front. Immunol. 14 (2023) 1146738.

[106] C. Pinto, K. Slavic-Obradovic, D. Fürweger, B. Thaler, A. Souabni, S. Carotta, et al., Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics, iScience 26 (4) (2023 Apr 21) 106381.

[107] S. Hockney, J. Parker, J.E. Turner, X. Todd, S. Todryk, R.G. Gieling, et al., Next generation organoid engineering to replace animals in cancer drug testing, Biochem. Pharmacol. 213 (2023 Jul 1) 115586.

[108] E. Shelkey, A. Dominijanni, S. Forsythe, D. Oommen, S. Soker, Modeling of the tumor microenvironment in tumor organoids [cited 2024 Feb 10]; Available from: https://books.rsc.org/books/edited-volume/2033/chapter/4649275/Modeling-of-the-Tumor-Microenvironment-in-Tumor, 2022 Dec 7.

[109] M. Najafi, K. Mortezaee, J. Majidpoor, Stromal reprogramming: a target for tumor therapy, Life Sci. 239 (2019 Dec 15) 117049.

[110] C. Guido, D. Whitaker-Menezes, C. Capparelli, R. Balliet, Z. Lin, R.G. Pestell, et al., Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth, Cell Cycle 11 (16) (2012 Aug 15) 3019–3035.

[111] Kamdje AH. Nwabo, P.F. Seke Etet, R. Simo Tagne, L. Vecchio, K.E. Lukong, M. Krampera, Tumor microenvironment uses a reversible reprogramming of mesenchymal stromal cells to mediate pro-tumorigenic effects [cited 2024 Feb 8], Frontiers in Cell and Developmental Biology [Internet] 8 (2020). Available from: https://www.frontiersin.org/articles/10.3389/fcell.2020.545126.

[112] P. Ghahremanifard, A. Chanda, S. Bonni, P. Bose, TGF-B mediated immune evasion in cancer—spotlight on cancer-associated fibroblasts, Cancers 12 (12) (2020 Dec 5) 3650.

[113] C. Devaud, L.B. John, J.A. Westwood, P.K. Darcy, M.H. Kershaw, Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy, OncoImmunology 2 (8) (2013 Aug 1) e25961.

[114] M. Kuske, M. Haist, T. Jung, S. Grabbe, M. Bros, Immunomodulatory properties of immune checkpoint inhibitors-more than boosting T-cell responses? Cancers 14 (7) (2022 Mar 28) 1710.

[115] J.A. Berzofsky, M. Terabe, L.V. Wood, Strategies to use immune modulators in therapeutic vaccines against cancer, Semin. Oncol. 39 (3) (2012 Jun) 348–357.
[116] M.P. Jogalekar, R.L. Rajendran, F. Khan, C. Dmello, P. Gangadaran, B.C. Ahn, CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments, Front. Immunol. 13 (2022 Jul 22) 925985.
[117] G.W. Tormoen, M.R. Crittenden, M.J. Gough, Role of the immunosuppressive microenvironment in immunotherapy, Adv Radiat Oncol 3 (4) (2018 Oct 23) 520–526.
[118] F. Kai, A.P. Drain, V.M. Weaver, The extracellular matrix modulates the metastatic journey, Dev. Cell 49 (3) (2019 May 6) 332–346.
[119] N.K. Karamanos, Z. Piperigkou, A. Passi, M. Götte, P. Rousselle, I. Vlodavsky, Extracellular matrix-based cancer targeting, Trends Mol. Med. 27 (10) (2021 Oct 1) 1000–1013.
[120] Y. Jiang, H. Zhang, J. Wang, Y. Liu, T. Luo, H. Hua, Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy, J. Hematol. Oncol. 15 (1) (2022 Mar 24) 34.
[121] G.B. Fields, Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases, Front. Immunol. 10 (2019 Jun 4) 1278.
[122] T. Paresishvili, Z. Kakabadze, Challenges and opportunities associated with drug delivery for the treatment of solid tumors, Onco Rev. 17 (2023 Aug 30) 10577.
[123] A. Hoeben, E.A.J. Joosten, M.H.J. van den Beuken-van Everdingen, Personalized medicine: recent progress in cancer therapy, Cancers 13 (2) (2021 Jan 11) 242.
[124] J. Gao, J. Lan, H. Liao, F. Yang, P. Qiu, F. Jin, et al., Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges, BMC Cancer 23 (1) (2023 Dec 7) 1205.
[125] Y. Wang, Y. Li, Z. Sheng, W. Deng, H. Yuan, S. Wang, et al., Advances of patient-derived organoids in personalized radiotherapy [cited 2024 Feb 8], Front. Oncol. 12 (2022). Available from: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.888416.
[126] M. Stakheyeva, V. Riabov, I. Mitrofanova, N. Litviakov, E. Choynzonov, N. Cherdyntseva, et al., Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy, Curr. Pharmaceut. Des. 23 (32) (2017) 4807–4826.
[127] Z.V. Braig, Personalized medicine: from diagnostic to adaptive, Biomed. J. 45 (1) (2022 Feb 1) 132–142.
[128] L. Zhong, Y. Liu, K. Wang, Z. He, Z. Gong, Z. Zhao, et al., Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma, BMC Cancer 18 (1) (2018 Sep 21) 911.
[129] X. He, Y. Jiang, L. Zhang, Y. Li, X. Hu, G. Hua, et al., Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer, Frontiers in Bioengineering and Biotechnology [Internet] 11 (2023). Available from: https://www.frontiersin.org/articles/10.3389/fbioe.2023.1190637.
[130] P. Krzyszczyk, A. Acevedo, E.J. Davidoff, L.M. Timmins, I. Marrero-Berrios, M. Patel, et al., The growing role of precision and personalized medicine for cancer treatment, Technology 6 (3–4) (2018) 79–100.
[131] G. Liang, W. Fan, H. Luo, X. Zhu, The emerging roles of artificial intelligence in cancer drug development and precision therapy, Biomed. Pharmacother. 128 (2020 Aug 1) 110255.
[132] A. Zhang, K. Miao, H. Sun, C.X. Deng, Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance, Int. J. Biol. Sci. 18 (7) (2022 Apr 24) 3019–3033.
[133] H. Li, L. Zhou, J. Zhou, Q. Li, Q. Ji, Underlying mechanisms and drug intervention strategies for the tumour microenvironment, J. Exp. Clin. Cancer Res. 40 (1) (2021 Mar 15) 97.
[134] N.L. de Vries, A. Mahfouz, F. Koning, N.F.C.C. de Miranda, Unraveling the complexity of the cancer microenvironment with multidimensional genomic and cytometric technologies, Front. Oncol. 10 (2020 Jul 23) 1254.